Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, Horgan K, Kirwan C, Mallon E, Sibbering M, Skene A, Vidya R, Cheang M, Banerji J, Morden J, Sidhu K, Dodson A, Bliss JM, Dowsett M. Smith I, et al. Among authors: evans a. Lancet Oncol. 2020 Nov;21(11):1443-1454. doi: 10.1016/S1470-2045(20)30458-7. Lancet Oncol. 2020. PMID: 33152284 Free PMC article. Clinical Trial.
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).
Leary A, Evans A, Johnston SR, A'Hern R, Bliss JM, Sahoo R, Detre S, Haynes BP, Hills M, Harper-Wynne C, Bundred N, Coombes G, Smith I, Dowsett M. Leary A, et al. Among authors: a hern r, evans a. Clin Cancer Res. 2015 Jul 1;21(13):2932-40. doi: 10.1158/1078-0432.CCR-14-1428. Epub 2014 Nov 14. Clin Cancer Res. 2015. PMID: 25398453 Clinical Trial.
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Gellert P, Segal CV, Gao Q, López-Knowles E, Martin LA, Dodson A, Li T, Miller CA, Lu C, Mardis ER, Gillman A, Morden J, Graf M, Sidhu K, Evans A, Shere M, Holcombe C, McIntosh SA, Bundred N, Skene A, Maxwell W, Robertson J, Bliss JM, Smith I, Dowsett M; POETIC Trial Management Group and Trialists. Gellert P, et al. Among authors: evans a. Nat Commun. 2016 Nov 9;7:13294. doi: 10.1038/ncomms13294. Nat Commun. 2016. PMID: 27827358 Free PMC article. Clinical Trial.
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
Gao Q, López-Knowles E, U Cheang MC, Morden J, Ribas R, Sidhu K, Evans D, Martins V, Dodson A, Skene A, Holcombe C, Mallon E, Evans A, Bliss JM, Robertson J, Smith I, Martin LA, Dowsett M; POETIC Trial Management Group and Trialists. Gao Q, et al. Among authors: evans d, evans a. JNCI Cancer Spectr. 2018 May 22;2(2):pky005. doi: 10.1093/jncics/pky005. eCollection 2018 Apr. JNCI Cancer Spectr. 2018. PMID: 31360844 Free PMC article.
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC. Garcia-Murillas I, et al. Among authors: evans a. JAMA Oncol. 2019 Oct 1;5(10):1473-1478. doi: 10.1001/jamaoncol.2019.1838. JAMA Oncol. 2019. PMID: 31369045 Free PMC article.
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer.
Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Buus R, Quang LH, Thi Han P, Khoa PH, Dinh NV, To TV, Clemons M, Holcombe C, Osborne C, Evans A, Skene A, Sibbering M, Rogers C, Laws S, Noor L, Smith IE, Dowsett M. Haynes BP, et al. Among authors: evans a. NPJ Breast Cancer. 2019 Nov 15;5:42. doi: 10.1038/s41523-019-0138-2. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31754627 Free PMC article.
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Cheung SYA, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW. Robertson JFR, et al. Among authors: evans a. Clin Cancer Res. 2020 Apr 1;26(7):1574-1585. doi: 10.1158/1078-0432.CCR-19-3053. Epub 2019 Dec 13. Clin Cancer Res. 2020. PMID: 31836609 Free article. Clinical Trial.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao Q, López-Knowles E, Cheang MCU, Morden J, Ribas R, Sidhu K, Evans D, Martins V, Dodson A, Skene A, Holcombe C, Mallon E, Evans A, Bliss JM, Robertson J, Smith I, Martin LA, Dowsett M; POETIC Trial Management Group and Trialists. Gao Q, et al. Among authors: evans d, evans a. Breast Cancer Res. 2019 Dec 31;22(1):2. doi: 10.1186/s13058-019-1223-z. Breast Cancer Res. 2019. PMID: 31892336 Free PMC article. Clinical Trial.
6,133 results